Table 2.
Management of SARS-CoV-2 infection in 32 dialysis and kidney transplant patients
| Characteristics | Positive outcome [13] | Negative outcome [19] | p |
|---|---|---|---|
| Patients on HD or PD | 5 | 12 | 0.280 |
| COVID-19 management | |||
| Dexamethasone | 2/5 | 8/12 | 0.593 |
| Tocilizumab | 0/5 | 1/12 | 1 |
| Hydroxychloroquine | 5/5 | 11/12 | 1 |
| Antivirals* | 5/5 | 12/12 | 1 |
| Antibiotics | 5/5 | 12/12 | 1 |
| Kidney transplant patients | 8 | 7 | 0.280 |
| Immunosuppression management | |||
| MMF, mTOR-I, CNI withdrawal | 8/8 | 7/7 | 1 |
| Glucocorticoids introduction or increase | 7/8 | 8/8 | 1 |
| COVID-19 Management | |||
| Dexamethasone | 1/8 | 4/7 | 0.12 |
| Tocilizumab | 0/8 | 4/7 | 0.026 |
| Hydroxychloroquine | 8/8 | 7/7 | 1 |
| Antivirals* | 8/8 | 7/7 | 1 |
| Antibiotics | 4/8 | 5/7 | 0.608 |
Patients were stratified according to the evolution of COVID-19 in a group with positive outcome (PosCOV, patients that did not die or develop ARDS) and in a group with negative outcome (NegCOV, patients that died or developed ARDS). Data are reported as number for categorical variables and median (interquartile range) for continuous variables
HD hemodialysis, PD peritoneal dialysis, CNI calcineurin inhibitors, mTOR-I mammalian target of rapamycin inhibitors, MMF mycophenolate mofetil
*Lopinavir/ritonavir, darunavir and ritonavir